Please assess the completion status of the following clinical trial:

Trial Title: Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting plasma Glucose- 126-270~* HbA1c \<10%~* Hematocrit \>34%~* Serum creatinine \<1.8mg/dl~* AST (aspartate aminotransferase) \< 2 times upper limit of normal~* ALT (Alanine aminotransferase) \< 2 time upper limit of normal~* Alkaline phosphatase \<2 times upper limit of normal~Exclusion Criteria:~* Type 1 DM~* Fasting plasma glucose \>270 mg/dl~* Thiazolidinedione therapy~* Insulin therapy in last 3 months~* Congestive heart failure \> NYHA (New York Heart Association) class II~* History of dyspnoea on exertion~* Abnormal breath sounds~* EKG changes other than non-specific ST-T changes in the ECG (Electro-CardioGram) or LVH (Left Ventricular Hypertrophy)~* H/O Claudication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): One arm of the study subjects will be treated with Placebo only, once a day, for 6 months
- Pioglitazone (Type: ACTIVE_COMPARATOR): One arm of the study subjects will be treated with Pioglitazone, 15mg, once a day, for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).